<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660231</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/06/009</org_study_id>
    <secondary_id>CRUK-UCL-GEMBEX</secondary_id>
    <secondary_id>EU-20841</secondary_id>
    <secondary_id>EUDRACT 2006-000591-33</secondary_id>
    <nct_id>NCT00660231</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma</brief_title>
  <acronym>GemBex</acronym>
  <official_title>A Phase II Study of Gemcitabine and Bexarotene (Gembex) in the Treatment of Cutaneous T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and bexarotene, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving gemcitabine together with bexarotene to see&#xD;
      how well it works in treating patients with progressive or refractory stage IB, stage II,&#xD;
      stage III, or stage IV cutaneous T-cell non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Confirm the feasibility and efficacy of the combination of gemcitabine hydrochloride and&#xD;
           bexarotene in patients with cutaneous T-cell lymphoma whose disease is no longer&#xD;
           controlled by skin-directed therapy and who have had at least one prior systemic&#xD;
           therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rate of objective disease control as defined by complete response (CR),&#xD;
           clinical complete response (CCR), partial response (PR), and stable disease (SD) for 6&#xD;
           months as determined by the Objective Primary Disease Response Evaluation Criteria&#xD;
           (OPDREC).&#xD;
&#xD;
        -  Evaluate the duration and durability of objective disease response (CR, CCR and PR) as&#xD;
           determined by OPDREC criteria.&#xD;
&#xD;
        -  Evaluate time to objective disease response.&#xD;
&#xD;
        -  Determine the safety of this combination in terms of adverse events, clinical laboratory&#xD;
           data, physical examinations, rate of neutropenic fever and sepsis, blood transfusions,&#xD;
           and treatment compliance.&#xD;
&#xD;
        -  Determine the time to objective disease progression.&#xD;
&#xD;
        -  Determine the time to treatment failure.&#xD;
&#xD;
        -  Determine change from baseline in Severity-Weighted Assessment Tool (SWAT) value,&#xD;
           Erythroderma SWAT value, Pruritus Visual Analogue Scale, and ECOG performance status.&#xD;
&#xD;
        -  Determine proportion of disease control, response, and progression as determined by&#xD;
           RECIST criteria.&#xD;
&#xD;
        -  Evaluate the proportion of patients with clearing of Sézary cells from the blood and&#xD;
           bone marrow.&#xD;
&#xD;
        -  Measure changes in patient assessed Quality of Life using Skindex 29 and EORTC QLQ-30.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride IV on days 1 and 8 and oral bexarotene daily on&#xD;
      days 1-21. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. After 4 courses of study therapy, patients with&#xD;
      responding disease receive oral bexarotene alone daily until disease progression or treatment&#xD;
      no longer tolerated.&#xD;
&#xD;
      Patients complete a quality of life questionnaire at baseline, during study therapy, and&#xD;
      after completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for up to 5 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of objective response</measure>
    <time_frame>at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and durability of objective disease response</measure>
    <time_frame>up to 5 years after treatment start</time_frame>
    <description>Time from first date of treatment to the first date of diagnosis of progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life</measure>
    <time_frame>up to 5 years after treatment start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>GemBex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
    <description>Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.</description>
    <arm_group_label>GemBex</arm_group_label>
    <other_name>Targretin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.</description>
    <arm_group_label>GemBex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous T-cell lymphoma (CTCL) including its variants&#xD;
             (e.g., mycosis fungoides and Sézary syndrome)&#xD;
&#xD;
               -  CTCL stage IB, IIA, IIB, III or IVA disease&#xD;
&#xD;
               -  No visceral involvement (i.e., stage IVB disease)&#xD;
&#xD;
                    -  Lymphadenopathy is allowed&#xD;
&#xD;
          -  Patients must have developed progressive disease after receiving or have been&#xD;
             refractory to at least 1 course of prior standard, systemic, skin-directed therapy&#xD;
             (e.g., interferon, chemotherapy, or denileukin diftitox [Ontak®])&#xD;
&#xD;
          -  No CD30 + (Ki1+ve) anaplastic large cell lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL (transfusions and/or erythropoietin are allowed)&#xD;
&#xD;
          -  ANC &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin ≤ 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 2 times ULN&#xD;
&#xD;
          -  No clinically significant active infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No excessive alcohol consumption&#xD;
&#xD;
          -  No biliary tract disease&#xD;
&#xD;
          -  No history of pancreatitis&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal or&#xD;
             squamous cell skin cancer, cervical epithelial neoplasm CIN1, or carcinoma in situ&#xD;
&#xD;
          -  No other significant medical or psychiatric condition that would preclude study&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since any prior investigational agent&#xD;
&#xD;
          -  More than 2 weeks since prior topical steroids or more than 4 weeks since prior&#xD;
             systemic steroids&#xD;
&#xD;
          -  Local radiotherapy may be given to isolated symptomatic tumour nodules that require&#xD;
             immediate treatment for up to 2 weeks prior to study drugs&#xD;
&#xD;
          -  No prior treatment with bexarotene (Targretin®)&#xD;
&#xD;
          -  No concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent investigational agent&#xD;
&#xD;
          -  No concurrent drug therapy with other medications that can elevate triglycerides or&#xD;
             cause pancreatic toxicity (e.g., gemfibrozil)&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Illidge</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>England</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IB mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IB cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

